Researchers already did studies in low-dose Aspirin for the prevention of heart and blood vessels disease and for the prevention of cancer of the colorectum. In this study, they want to learn whether an effect for the prevention of oesophagus cancer and stomach cancer goes along with the use of low-dose ASA on patients taking this medicine for the prevention of heart and blood vessels disease compared to non-use. To find this out electronic medical records stored in primary care database in the UK, The Health Improvement Network (THIN), will be used.
Study Type
OBSERVATIONAL
Enrollment
99,999
Administration according to clinical practice
Many locations
Multiple Locations, United Kingdom
Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA overall compared to non-use
Diagnosis of cancer is routinely recorded by means of Read codes in THIN database
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by age compared to non-use
Age: 40-64 years, 65-74 years and 75 and more years.
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-use
Sex: Male, Female
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Duration of low-dose ASA
Duration of treatment will be calculated among current users.
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Dose-response of low-dose ASA
The following daily doses will be ascertained: 75 mg, 150 mg and 300 mg.
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Number of case-fatality of oesophageal cancer and stomach cancer among new users of low-dose ASA
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA for primary or secondary cardiovascular prevention
The primary and secondary cardiovascular prevention population of low-dose ASA users will be defined using a computer algorithm ascertaining any recorded Read code suggestive of cardiovascular disease (CVD).
Time frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.